KRAS and cancer: Hence, understanding variations in KRAS mutational frequencies, clinicopathological characteristics, and comutations for KRASG12C tumors across cancer types, as well as their interplay with predictors of response to immune checkpoint inhibitors, may advance the clinical development of KRASG12C inhibitors.